We are live on ! Find out more
SBBP

Strongbridge Biopharma plc.
SBBP

Delisted

SBBP was delisted on the 5th of October, 2021.

Back to rankings

58 hedge funds and large institutions have $49.7M invested in Strongbridge Biopharma plc. in 2019 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 24 increasing their positions, 10 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

140% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 10

36% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 11

7% more funds holding

Funds holding: 54 → 58 (+4)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

23% less capital invested

Capital invested by funds: $64.8M → $49.7M (-$15.2M)

Holders
58
Holders Change
+4
Holders Change %
+7.41%
% of All Funds
1.14%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
15
Increased
24
Reduced
10
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$1.9M
2
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
+$1.15M
3
Renaissance Technologies
Renaissance Technologies
New York
+$834K
4
SCM
Stonepine Capital Management
Oregon
+$828K
5
DT
Diversified Trust
Tennessee
+$381K

Top Sellers

Rank Fund Capital Flow
1
BC
Broadfin Capital
New York
-$6.16M
2
PM
Prosight Management
Texas
-$2.41M
3
2L
22NW LP
Washington
-$1.92M
4
OM
Opaleye Management
Massachusetts
-$1.17M
5
BlackRock
BlackRock
New York
-$1.02M
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of Montreal
26
Bank of Montreal
Ontario, Canada
$139K +$120K +62,390 +1,523%
California State Teachers Retirement System (CalSTRS)
27
California State Teachers Retirement System (CalSTRS)
California
$116K – – –
Morgan Stanley
28
Morgan Stanley
New York
$104K +$71.2K +37,145 +298%
UBS Group
29
UBS Group
Switzerland
$102K +$46.9K +24,486 +100%
Acadian Asset Management
30
Acadian Asset Management
Massachusetts
$101K +$72.2K +37,669 +337%
OAM
31
Oxford Asset Management
United Kingdom
$93K +$6.68K +3,483 +8%
RhumbLine Advisers
32
RhumbLine Advisers
Massachusetts
$81K +$1.16K +606 +2%
New York State Common Retirement Fund
33
New York State Common Retirement Fund
New York
$77K – – –
Barclays
34
Barclays
United Kingdom
$77K +$34K +17,718 +92%
AC
35
Aristides Capital
Kentucky
$74K +$68.1K +35,517 New
Goldman Sachs
36
Goldman Sachs
New York
$71K +$9.23K +4,814 +16%
Deutsche Bank
37
Deutsche Bank
Germany
$69K +$46.8K +24,411 +268%
PAM
38
Panagora Asset Management
Massachusetts
$69K +$59.5K +31,057 +1,348%
Ameriprise
39
Ameriprise
Minnesota
$64K +$58.9K +30,710 New
AIG
40
American International Group
New York
$47K -$366 -191 -0.8%
ARTA
41
A.R.T. Advisors
New York
$45K +$41K +21,387 New
HF
42
HRT Financial
New York
$35K +$32.2K +16,788 New
Susquehanna International Group
43
Susquehanna International Group
Pennsylvania
$32K -$5.6K -2,921 -16%
P
44
&Partners
Tennessee
$31K +$28.8K +15,000 New
Citadel Advisors
45
Citadel Advisors
Florida
$31K +$29K +15,113 New
CF
46
Centaurus Financial
California
$21K +$19.2K +10,000 New
BNP Paribas Financial Markets
47
BNP Paribas Financial Markets
France
$18.1K +$13.4K +6,978 +420%
Citigroup
48
Citigroup
New York
$15K +$9.46K +4,934 +211%
Legal & General Group
49
Legal & General Group
United Kingdom
$13K – – –
Nisa Investment Advisors
50
Nisa Investment Advisors
Missouri
$13K – – –
1
2
3

SBBP Hedge Fund Activity: Q4 2019 in Review

58 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Strongbridge Biopharma plc. (SBBP) for Q4 2019, worth a combined $49.7M — down 23% from $64.8M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new SBBP positions and 11 closed out — a net gain of 4 holders — while 24 added to existing stakes and 10 trimmed.

The largest buyer was Vanguard Group, adding an estimated $1.9M. The largest seller was Broadfin Capital, exiting entirely with an estimated $6.16M sold.

  • 58 institutional investors held Strongbridge Biopharma plc. (SBBP) as of Q4 2019, up from 54 in Q3 2019.
  • Funds reported $49.7M of Strongbridge Biopharma plc. stock for Q4 2019, down 23% quarter-over-quarter.
  • 15 funds opened new Strongbridge Biopharma plc. positions in Q4 2019 and 11 closed out, a net change of +4 holders.
  • The largest Strongbridge Biopharma plc. buyer in Q4 2019 was Vanguard Group, an estimated $1.9M added.
  • The largest Strongbridge Biopharma plc. seller in Q4 2019 was Broadfin Capital, an estimated $6.16M sold.

Based on aggregated 13F filings for Q4 2019.